Akebia Therapeutics, Inc.

AKBA

$0.94

+2.82%

2026-09-01 16:00:01 EDT+$0.03

Healthcare

Biotechnology

NASDAQ

Active Trading

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for ...

Price Action of AKBA

$0.94

+2.82%+$0.03

High—

Low—

52W High-70.5%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a fully integrated biopharmaceutical company founded in 2007 with the purpose of bettering the lives of people impacted by kidney disease. The company is headquartered in Cambridge, Massachusetts and operates in the biotechnology industry. It leverages hypoxia-inducible factor (HIF) biology to develop novel therapeutics ...Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a fully integrated biopharmaceutical company founded in 2007 with the purpose of bettering the lives of people impacted by kidney disease. The company is headquartered in Cambridge, Massachusetts and operates in the biotechnology industry. It leverages hypoxia-inducible factor (HIF) biology to develop novel therapeutics aimed at setting new standards of care for renal patients. Akebia's key products include Auryxia (ferric citrate), which manages serum phosphorus levels in adult CKD patients on dialysis and treats iron deficiency anemia in non-dialysis CKD patients, and vadadustat, an oral HIF-PH inhibitor in Phase III trials for anemia due to CKD. The company has strategic collaborations with Otsuka Pharmaceutical for vadadustat in major markets, Mitsubishi Tanabe Pharma for Japan/Asia, and Janssen for HIF-PH compounds. Financially, Akebia has a market cap of approximately $228 million, with a gross profit margin of 79.5% but a net profit margin of -13.5% (TTM). It employs 194 people and operates with a revenue of about $219 million. The company emphasizes research and development, with R&D expenses at 32% of revenue, and remains committed to improving patient outcomes through innovative treatments.ExpandCollapse

Founded

2007

Employees

194

CEO

John Butler

Full Name

Akebia Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-93.74%

Market Cap

$0.25B

Current Ratio

1.43

WACC

8.19%

ROIC

-15.69%

Contact Information

https://www.akebia.com

617 871 2098

245 First Street, Cambridge, MA 02142

Key Metrics of AKBA

Snapshot

Latest / TTM · 6 periods

Market Cap

$253.42M

ROCE

-8.0%

EV / EBITDA

-9.01x

-19.0% YoY

FCF Yield

15.3%

-1.2% YoY

Cash Conversion Cycle

118.3d

Current Ratio

1.43

Quick take

TTM —

Positive CCC

Financial Highlights of AKBA

Profitability trend

Latest / TTM · 6 periods

Gross Margin

79.5%

Net Margin

-13.5%

P/E Ratio

-9.10x

n/a

Debt / Equity

2.16

n/a

Current Ratio

1.43

Dividend Yield

0.0%

Understanding

TTM —

High debt to equity

Interest coverage is weak

Calendar of AKBA

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.04 · Revenue $46.55M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.05 · Revenue $47.54M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.15 · Revenue $196.84M · 2 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.09 · Revenue $32.58M · 1 analysts

Recent history

Aug 5, 2026
Q2 FY2026 · Results reported
EPS $-0.03 · Revenue $49.13M
View filing
May 7, 2026
Q1 FY2026 · Results reported
EPS $-0.03 · Revenue $53.54M
View filing
Feb 26, 2026
FY2025 · Annual results
EPS $-0.02 · Revenue $236.20M
View filing
Nov 10, 2025
Q3 FY2025 · Results reported
EPS $0.00 · Revenue $58.77M
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $0.00 · Revenue $62.47M
View filing
May 8, 2025
Q1 FY2025 · Results reported
EPS $0.03 · Revenue $57.34M
View filing

Financial Statements of AKBA

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$236.2M	+47.5%	-8.2%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-5.3M	+92.3%	+1.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+83.3%	+37.5%	+3.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+9.9%	+131.6%	-46.8%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-2.3%	+94.8%	-7.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$68.0M	+267.1%	+111.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+28.8%	+213.3%	+112.6%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	663.3%	+272.9%	+372.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.13x	-19.4%	+1.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$376.6M	+70.6%	-3.5%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.02 vs 0.00	-754.1%	-0.03 vs -0.03	+8.0%
Revenue Surprise	$236.2M vs $229.2M	+3.0%	$49.1M vs $48.9M	+0.6%

Insider Transactions of AKBA

Acquisitions (A)

Since Jun 17, 2026

Disposals (D)

Since Jun 17, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 6, 2026	Butler John P.	director, officer: CEO and President	Common Stock	A	350,000	$0.63
Aug 6, 2026	Butler John P.	director, officer: CEO and President	Stock Option (Right to buy)	D	350,000	$0.63
Jun 29, 2026	Ostrowski Erik	officer: SVP, CFO, CBO & Treasurer	Common Stock	D	56,019	$1.11
Jun 17, 2026	Wolf Myles	director	Common Stock	A	35,700	—
Jun 17, 2026	Wolf Myles	director	Stock Option (Right to buy)	A	53,600	$1.02

Earnings Call Transcript of AKBA

1 transcript segments

Q1 2026

Unknown Speaker

Operator: Good day, and thank you for standing by. Welcome to Akebia's First Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Mercedes Carrasco. Please go ahead. Mercedes Carrasco: Thank you, and welcome to Akebia's First Quarter 2026 Financial Results and Business Update Conference Call. Please note that a press release was issued earlier today, Thursday, May 7, detailing our first quarter 2026 financial results, and that release is available on the Investors section of our website. For your convenience, a replay of today's call will be available on our website after we conclude. Joining me for today's call, we have John Butler, Chief Executive Officer; Nick Grund, Chief Commercial Officer; and Erik Ostrowski, Chief Financial and Chief Business Officer. Dr. Steven Burke, our Chief Medical Officer, will also be available during Q&A. I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in the financial results press release that we issued on May 7 as well as in the Risk Factors and Management Discussion and Analysis section of our most recent annual and quarterly reports filed with the SEC. With that, I'd like to introduce our CEO, John Butler. John Butler: Thanks, Mercedes, and thanks to all of you for joining us this morning. We are very pleased and excited by the start to 2026. I want to focus on 3 key areas that we feel we need to execute on to create near- and long-term value for patients and shareholders. First, we have to drive the near-term launch performance of Vafseo. Second, continue to build the clinical evidence to make Vafseo standard of care for patients on dialysis; and third, execute on our impressive kidney disease-focused clinical development pipeline. We've made important progress across each of these areas. Starting with the Vafseo launch, revenues were nearly $16 million in Q1, representing our highest quarter of Vafseo net product revenue to date and demonstrating the growth we expected over Q4 2025. We're pleased with the progress we're seeing within and across dialysis organizations as we expand the breadth and depth of prescribing and continue to educate the nephrology community on the benefits of Vafseo. We believe this growth is being driven by dialysis organizations that have chosen to implement an observed dosing protocol. Nick is going to expand on that important point and provide more detail on the quarter and trends we're seeing in 2026. Now we continue to work to take advantage of the TDAPA opportunity for the balance of '26. Of course, we're already planning for the beginning of 2027 when Vafseo …

Leadership Team of AKBA

9 executives

Name	Title	Compensation	Gender	Year Born	Status
John Butler	Chief Executive Officer, President & Director	USD 1,463,203	Male	1964	Active
Carolyn Rucci	Senior Vice President, Chief Legal Officer & Secretary	USD 933,304	Female	1981	Active
Steven Keith Burke	Senior Vice President and Chief Research & Development Officer	USD 860,324	—	1961	Active
Erik John Ostrowski	Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer	USD 792,870	Male	1972	Active
Nicholas Grund	Senior Vice President & Chief Commercial Officer	USD 728,914	Male	1970	Active
Mercedes Carrasco	Senior Director of Investor & Corporate Communications	—	—	—	Active
Richard C. Malabre	Senior VP & Chief Accounting Officer	—	Male	1961	Active
Meredith Bowman	Senior Vice President & Chief People Officer	—	Female	—	Active
Justin McCue	Senior VP & Chief Technology Officer	—	—	—	Active

Recent News of AKBA

Seeking Alpha8/5/2026Neutral

Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript

Zacks Investment Research8/5/2026Neutral

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.

MarketBeat8/5/2026Neutral

Akebia Therapeutics Q2 Earnings Call Highlights

Akebia Therapeutics NASDAQ: AKBA reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its kidney disease pipeline.

GlobeNewsWire8/5/2026Neutral

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million ; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; initial data expected in 2027 Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 CAMBRIDGE, Mass.

GlobeNewsWire8/3/2026Neutral

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 2 newly-hired employees options to purchase an aggregate of 61,000 shares of Akebia's common stock on July 31, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Historical Employee Count of AKBA

Current

194

Change

+7.18%

Minimum

167

Maximum

426

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	194	10-K	Feb 26, 2026	View
Dec 31, 2024	181	10-K	Mar 13, 2025	View
Dec 31, 2023	167	10-K	Mar 14, 2024	View
Dec 31, 2022	205	10-K	Mar 10, 2023	View
Dec 31, 2021	426	10-K	Mar 1, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Akebia Therapeutics, Inc.